7 out of 10 emergency physicians say emergency department violence is increasing and half have been physically assaulted at work. Not only does violence harm patient care, it is costly to hospitals.
One of the main sources of Emergency Department violence is patients diagnosed with acute agitation and aggression, which accounts for approximately 10% of emergency room visits. Common causes include alcohol and drug use, mental illness, and dementia.
When these patients demonstrate violent behavior, it not only harms care providers, it also harms them. The underlying cause of their agitation and aggression cannot be diagnosed until they are calm. When trying to sedate these patients, minutes matter.
The two most common benzodiazepine treatments for emergency sedation today are intramuscular injection of diazepam or lorazepam. Diazepam is a fast-acting injectable sedative with optimal 2-4-hour duration of action, allowing timely re-evaluation of the patient’s condition. Diazepam, however, is very soluble in the fat tissue surrounding the injection site. This results in highly unpredictable absorption and onset of action when injected intramuscularly, limiting its use.
Lorazepam is the preferred benzodiazepine for the treatment for acute agitation and aggression. While it’s onset of action is predictable, yet slow. It can take up to 30-40 minutes to start working and its longer duration of action 6-8 hours means patients cannot be re-evaluated in a timely manner.
When surveyed, emergency physicians stated that rapid onset of action and safety are the largest unmet needs for sedatives in emergency setting.
Sollievo’s benzodiazepine pro-drug has demonstrated a 70% faster time to peak concentration than the leading sedative, lorazepam. With a 2-4-hour duration of action, Proviza offers fast sedation and predictable performance. Sollievo's proprietary technology is key to turbocharging Proviza’s absorption from the injection site.
When presented with the pro-drug’s product profile, 76% of emergency physicians state that they would prescribe the pro-drug when as soon as available. They estimate they would prescribe Proviza for acute agitation and aggression 60% of the time compared to 22% for lorazepam.
Fast and predictable sedation can improve safety for healthcare workers and the patients they serve. Patients with acute agitation and aggression may receive delayed diagnosis and treatment if they are exhibiting violent behavior. Sollievo’s Proviza is the first major innovation in intramuscular injectable benzodiazepines in over 30 years. It’s time to improve safety; it’s time to make a change.
Contains a new drug for investigational use only
Copyright © 2021 Sollievo Pharmaceuticals - All Rights Reserved.
Powered by Captjur